Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Friendly Bacteria Found in Probiotic Drinks May Shrink Solid Tumors

By BiotechDaily International staff writers
Posted on 15 Apr 2013
Friendly bacteria typically found in probiotic drinks could be used to shrink tumors, according to new research.

Researchers, from the University of Ulster (Northern Ireland) and Sonidel, Ltd. (Dublin, Ireland), examined the effect on tumors of the common Lactobacillus casei, which is found in the gut and human mouth, and a substance used in many probiotic drinks.

When injected directly into tumors, the new findings suggest that L. Casei could suppress tumor growth. Earlier studies suggest that specific kinds of bacteria grow well in solid tumors, which created the potential to use these kinds of bacteria to degrade tumors from the inside out. This study was structured to evaluate the hypothesis using a harmless kind of bacteria—L. Casei was a good candidate.

The researchers cultured the bacteria in beads, inside a growth solution. The research revealed that the bacteria generate molecules that are toxic to tumors. To further assess the hypothesis, the researchers then injected the encapsulated bacteria directly into tumors in lab mice. The bacteria substantially suppressed tumor growth. These research findings suggest that this approach has a potential therapeutic benefit in the treatment of solid tumors.

The study’s findings were published December 2012 in the International Journal of Medical Microbiology.

Related Links:

University of Ulster
Sonidel




Channels

Genomics/Proteomics

view channel
Image: Transmission electron micrograph of norovirus particles in feces (Photo courtesy of Wikimedia Commons).

Norovirus Interacts with Gut Bacteria to Establish a Persistent Infection That Can Be Blocked by Interferon Lambda

A team of molecular microbiologists and virologists has found that norovirus requires an intimate interaction with certain gut bacteria to establish a persistent infection, and that the infective process... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.